Author:
Palm Stig,Bäck Tom,Aneheim Emma,Hallqvist Andreas,Hultborn Ragnar,Jacobsson Lars,Jensen Holger,Lindegren Sture,Albertsson Per
Funder
Cancerfonden
Vetenskapsrådet
Stiftelsen Jubileumsklinikens Forskningsfond mot Cancer
Reference32 articles.
1. Targeted alpha therapy, an emerging class of cancer agents: a review;Targeted Alpha Therapy Working G;JAMA Oncol.,2018
2. Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model;Andersson;Clin. Cancer Res.,2003
3. Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: outcome related to measured tumor size and mean absorbed dose;Elgqvist;J. Nucl. Med.,2006
4. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab′)2—a phase I study;Andersson;J. Nucl. Med.,2009
5. Absorbed doses and risk estimates of (211)At-MX35 F(ab′)2 in intraperitoneal therapy of ovarian cancer patients;Cederkrantz;Int. J. Radiat. Oncol. Biol. Phys.,2015
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献